Clinical Trial Update: TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003) [Phase 2]

View source ↗

Summary

Phase 2 trial update for TAS-102 in previously treated unresectable or metastatic squamous cell lung carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Lung Carcinoma

Drugs mentioned

• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: University of Florida | Conditions: Squamous Cell Lung Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-12-17